Q-omics provides the consensus-scored PHC2-AS1 profile across patient tissues and cancer cell-line models. PHC2-AS1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PHC2-AS1 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, PHC2-AS1 RNA expression shows 13,082 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight KIRC, BLCA, and LAML as cancer lineages where PHC2-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHC2-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHC2-AS1 survival associations across molecular data types. PHC2-AS1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHC2-AS1 RNA expression–survival associations across cancer types. High PHC2-AS1 expression shows unfavorable associations in KIRC, COAD and KICH, but favorable associations in UCS, BRCA and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PHC2-AS1 RNA expression.
This table summarizes PHC2-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for PHC2-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHC2-AS1 shows lower tumor expression in THCA and higher tumor expression in BLCA, HNSC, LUSC, UCEC and CHOL. The BLCA box plot shows higher PHC2-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.627, t-test p < 0.001).
This table shows molecular features associated with PHC2-AS1 in patient tissues and cancer cell lines. In patient samples, PHC2-AS1 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
